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Abstract: We have reported a novel procedure to prepare 3,5-dihydroxy-4-isopropylstilbene 
(DHPS) nanoemulsion, using a low-energy emulsification method. Based on the phase diagram, 
the optimum prescription of nanoemulsion preparation was screened. With polyoxyethylenated 
castor oil (EL-40) as the surfactant, ethanol as the co-surfactant, and isopropyl myristate (IPM) as 
the oil phase, the DHPS nanoemulsion was obtained with a transparent appearance, little viscos-
ity, and spherically uniform distribution verified by transmission electron microscopy and laser 
scattering analyzer. The nanoemulsion was also determined by FT-Raman spectroscopy. The 
DHPS nanoemulsion demonstrated good stability and stable physical and chemical properties. 
The nanoemulsion dramatically improved the transdermal release of DHPS (from 8.02 µg ⋅ cm-2 
to 273.15 µg ⋅ cm-2) and could become a favorable new dosage form for DHPS.
Keywords: nanoemulsion, 3,5-dihydroxy-4-isopropylstilbene, DHPS, pseudo-ternary phase 
diagram
Introduction
3,5-Dihydroxy-4-isopropylstilbene (DHPS) (also named 2-isopropyl-5-(2-
phenylethenyl)-benzene-1,3-diol) belongs to the stilbene family and was first iden-
tified as a bacterial metabolite of the antimicrobial compound.1–5 This compound 
has attracted much attention for its diversified pharmacological activities including 
anti-inflammation and marked effect on T lymphocytes, mast cells, neutrophils, and 
macrophages.6,7 After the rapid progress in pharmacological studies, DHPS has been 
proposed to serve as an effective drug for many diseases such as inflammatory bowel 
disease, rheumatoid arthritis, and autoimmune skin disorders. At the beginning of the 
twenty-first century, DHPS (numbered WBI-2001) was developed by Welichem Bio-
tech Inc. (Burnaby, BC) as a new drug for atopic dermatitis and psoriasis, which are 
chronic skin diseases caused by a disorder of the autoimmune system.8,9 In the prior 
clinical trials in Canada, DHPS was shown to be effective and safe.10 In 2009, Celestial 
Pharmaceuticals (Shenzhen) Co Ltd (China) had also gained approval from the State 
Food and Drug Administration (SFDA) for the clinical trials of DHPS (Benvitimod) in 
China. However, the drug’s instability and insolubility in water resulted in the alteration 
of properties and poor skin permeability. Therefore, the drug had no curative effect. 
To overcome the problem, it is necessary to seek a new vehicle to elevate the stability 
and solubility of DHPS in water and promote skin permeability.
Nanoemulsion is a new drug delivery system possessing isotropic, optical transpar-
ency or translucence characteristics and of special concern for practical applications.11,12 
Nanoemulsions can be applied in the pharmaceutical field as drug delivery systems International Journal of Nanomedicine 2011:6
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not only for oral administration,13,14 but also for parenteral,15 
or transdermal administration,16 especially ocular.17 The 
drug is placed in the center of a small nanoemulsion droplet, 
30–300 nm, and is protected from oxidation, hydrolysis, and 
volatilization. Nanoemulsions have been reported to extend 
the drug response time and improve the efficacy of poorly 
water-soluble drugs as well as bioavailability.18–20 To date, 
compared with the oral carriers, few studies on nanoemulsion 
as topical carriers have been published. But it is still expected 
to be applied in topical delivery, taking advantage of good 
solubility, low skin irritation, and great permeability.21 In this 
work, we aimed to establish an oil-in-water (O/W) nanoemul-
sion delivery system for transdermal administration, in which 
DHPS was incorporated into the nanoemulsion concentrate 
so that the solubility and skin permeability of DHPS, and its 
therapeutic efficacy, could be dramatically enhanced.16,22,23 
Literature reviews have so far revealed no studies on the 
nanoemulsion as a delivery system for DHPS, including the 
preparation and release study of DHPS nanoemulsion. In 
this study, we prepared and characterized DHPS nanoemul-
sion, and investigated its transdermal in vitro release and its 
effect as an active drug on the stabilities of the concentrate 
and corresponding nanoemulsion.
Methods
Materials
DHPS (structure shown in Scheme 1) was synthesized in 
the laboratory,24 and isopropyl myristate (IPM) was bought 
from Shanghai LEASUN Chemical Co. Ltd (Shanghai, 
China). Various surfactants such as polyoxyethylene sorbitan 
fatty acid esters (Tween-80) and polyoxyethylenated castor 
oil (EL-40) were purchased from Tianjin Yongda Chemical 
Reagent Development Center (Tianjin, China). Methanol 
was chromatographically pure and purchased from Kangkede 
(Tianjin, China). Other chemical reagents were all analyti-
cally pure grades and purchased from Shijiazhuang Modern 
Reagent Co (Shijiazhuang, China). Soy bean salad oil, olive 
oil, and peanut oil were all of food grade and purchased from 
COFCO (Tianjin, China). Water was twice distilled.
characterization analyses
The process of identifying the structural type of the nano-
emulsion via staining is as follows: the water-soluble meth-
ylthionine chloride and oil-soluble Sudan red were added to 
the same batch of the nanoemulsion. The diffusion rate of two 
kinds of staining agents in the nanoemulsion was recorded. 
The transmission electron microscopy (TEM, H-7650; 
Hitachi, Tokyo, Japan) was used to monitor the morphology 
and distribution of nanoemulsion droplets and FT-Raman 
spectroscopy (MultiRam; Bruker, Madison, WI) was used to 
determine the components. The mean size of nanoemulsion 
droplets was detected by Laser Scattering Analyzer (Nano-
S90; Malvern Instruments, Malvern, Worcestershire, UK). 
The amount of DHPS in the solubility and stability experi-
ments, and in vitro transdermal release, was detected by high-
performance liquid chromatography (HPLC, LC-10AT VP; 
Shimadzu, Kyoto, Japan). The mobile phase was a mixture 
of methanol and distilled water (V/V = 80/20). The column 
of HPLC was Phenomenexluna-C18 (250 × 4.6 mm, 5 µm). 
The flow rate was 1.0 mL/minute, the detection wavelength 
was 316 nm, and the injected volume of the sample was 
10 µL. The in vitro transdermal release experiment of DHPS 
nanoemulsion was carried out through rat skin in a Franz 
diffusion cell (RYJ-12B, Huanghai, China).
solubility of DhPs
Achieving good solubility of drugs in the studied surfactants, 
co-surfactants, oil mediums, and their emulsifier is important 
in the development of nanoemulsions. EL-40 and Tween-80 
were chosen as non-ionic surfactants, and ethanol, i-propanol, 
1,2-propanediol, and n-butanol were used as short-chain co-
surfactants. Frequently used liquid paraffin, IPM, soybean 
oil, and olive oil were used as oil mediums. The solubility 
performance of DHPS in the above components and their 
emulsifier were observed. Different proportions of the above 
components and DHPS were placed in small vials. The vials 
were vibrated in a water bath at 37°C for 24 hours, and 
then the solubilities of DHPS in different components were 
determined by HPLC.
Phase diagrams
The methods for the formation of nanoemulsions include high-
energy and low-energy emulsification. Mechanical energy 
(such as high shear stirring, high-pressure homogenizers, and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ultrasound generators) was utilized in a high-energy emulsi-
fying process25 and chemical energy (potential energy) in the 
components was used in a low-energy emulsifying process.26 
Compared with the high-energy formation of nanoemulsions, 
the low-energy emulsification method has a strong appeal in 
the development of a drug delivery system, which can take 
advantage of phase behavior, industial scale-up, reduced 
physical destruction of drugs, and the formation of smaller 
droplets.27–29 The low-energy methods are divided into phase 
inversion composition30 and phase inversion temperature (PIT) 
methods.31,32 Nanoemulsions prepared by phase inversion com-
position are strongly affected by compositions in the system and 
their instrinsic physicochemical properties.33 During the phase 
inversion composition emulsification process, as the compo-
nents change (oil phase mixed with aqueous phase), the rapid 
transfer of hydrophilic materials between two phases is spon-
taneously generated.26 The interfacial area increased markedly, 
and a metastable emulsion state was generated. Therefore, the 
composition of components and their ratios strongly influence 
the formation of nanoemulsions and, simultaneously, their 
properties, such as the stability and distribution of particle 
size.34–36 For this reason, it is essential to establish a pseudo-
ternary phase diagram in order to determine the existing region 
of the nanoemulsion. The phase diagrams were developed 
using the aqueous titration method with one axis representing 
the composition of SF and Co-SF, another representing water, 
and the third representing oil; the nanoemulsion region would 
be the basis for the selection of the formulation.
The emulsifiers and oil mediums were sealed in ampoules 
and vibro-mixed gently to be homogenized at 25°C. Distilled 
water was then added continuously to the homogenized 
mixture. The phase inverse points and the mass ratio of all 
components corresponding to that point were recorded dur-
ing the consecutive addition of distilled water, and then the 
boundary lines appeared. The isotropic liquid crystal line 
phase was identified by polarizing light microscopy (PLM, 
BX51; Olympus, Tokyo, Japan).
Preparation of nanoemulsion
A certain amount of DHPS was dissolved in co-surfactant 
at a constant temperature in a vial. The oil mediums, sur-
factants, and solution of co-surfactant with DHPS were 
thoroughly mixed. Distilled water was added continuously to 
the mixed liquid. As the amount of distilled water increased, 
the system suddenly became viscous, and liquid crystals 
appeared. The distilled water was added drop-wise until a 
stable, colorless, and transparent or translucent nanoemul-
sion was formed.
selection of surfactant and co-surfactant
EL-40 and Tween-80 were chosen as non-ionic surfactants, 
and ethanol, i-propanol, 1,2-propanediol, and n-butanol were 
used as short-chain co-surfactants. IPM was used in the oil 
phase, according to oil solubility studies. The tests were 
designed under different Km (mass ratio of surfactant to co-
surfactant) as 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, and the 
corresponding mass ratio of the combination of surfactant and 
co-surfactant (Smix) to IPM was varied as 1:9, 2:8, 3:7, 4:6, 
5:5, 6:4, 7:3, 8:2, 9:1. The oil, surfactant, and co-surfactant 
of each group were well mixed to form an emulsion, and the 
total mass of all components was constant. Distilled water was 
added drop by drop into the emulsifier under ambient tempera-
ture. The emulsion appeared transparent and translucent, with 
low viscosity, and the Tyndall effect was observed. We noted 
that sometimes the system changed from clarity to turbidity, 
or from clarity to thickness, or back again from thickness to 
clarity, and noted down the quality percentage of all the com-
ponents corresponding to the phase inversion point.
Optimization of the formulation
To obtain an effective emulsification, the surfactant and 
co-surfactant are usually combined. The mixing ratio of 
surfactant/co-surfactant, to form nanoemulsions, also needs 
careful consideration. Surfactant (EL-40) and co-surfactant 
(ethanol) were mixed in different mass ratios (6:1, 4.5:1, 3:1, 
1.5:1). For each group, IPM and the mixture of surfactant–
co-surfactant with specific Km were mixed well in a series 
of mass ratios ranging from 1:9 to 9:1.
stability study of DhPs nanoemulsion
In order to avoid a metastable system, we performed various 
stability studies such as bearing centrifuging, heat, humid-
ity, and light irradiating. The prepared formulations were 
sealed in the centrifuge tube and centrifuged at 10000 rpm 
for 20 minutes. Phase separation (cracking or creaming) 
was observed. If DHPS nanoemulsion showed no instability 
during the centrifugation process, its stability was assessed 
according to the regulations of Chinese Pharmacopoeia37 
including the high temperature test, high humidity test, 
and hard light irradiating test. The relative specifications of 
DHPS nanoemulsion were evaluated with sampling at 0, 5, 
and 10 days, respectively.
In vitro transdermal release
The abdominal skin of a mouse (25 ± 2 g, female, Kunming, 
China), which was depilated with 8% sodium sulfide and 
cleaned of fat, was washed with saline and then fixed to International Journal of Nanomedicine 2011:6
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Figure 1 The solubility of DhPs in various components.
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the Franz diffusion cell. The horny layer of skin faced the 
supply chamber, and 1.0 g DHPS nanoemulsion was added, 
in close contact with the skin. Sixteen milliliters of 0.9% 
sodium chloride solution (M/M ) was used as the receiving 
medium. The temperature of the receiving medium was 
kept at 37 ± 0.5°C and the rotating speed was controlled 
at 120 rpm. At certain time intervals (0.5, 1, 2, 4, 6, 8, 10, 
and 12 hours), 5 mL receiving medium was taken out of the 
supply chamber and, simultaneously, an equal volume of 
fresh receiving medium was added to the supply chamber 
to keep the total volume unchanged. Released DHPS was 
quantified by HPLC and the cumulative release rate was 
calculated. During the in vitro transdermal experiment, the 
release behavior of the DHPS nanoemulsion was compared 
with that of the drug DHPS (20 mg DHPS suspended in 
the supply chamber). All the experiments were carried out 
in triplicate. The release behavior of DHPS nanoemulsion 
was compared with that of pure DHPS suspension. The 
accumulative osmotic quantity per unit area (Qt) can be 
described as:
 
Qt =∑CV iA i /
where Ci is the DHPS concentration in the tested samples, 
Vi is the volume of the receiving pool, and A is the effective 
area of the receiving pool.
Results
solubility of DhPs
As shown in Figure 1, DHPS is almost insoluble in distilled 
water and liquid paraffin, but has reasonable solubility in IPM, 
Tween-80, and EL-40. The solubility of the drug in the com-
ponents is important for component screening,38 and therefore, 
IPM was selected as the oil phase, and Tween-80 and EL-40 
were chosen as the surfactants in the nanoemulsion   formulation. 
The four co-surfactants all have favorable solubility for DHPS, 
although of the four co-surfactants, ethanol had the most 
advantages. The emulsifier formulations consisted of surfactant 
(EL-40), co-surfactant (ethanol), and drug dissolved in the oil 
(IPM) to provide a clear liquid at ambient temperature. The test 
results showed that the emulsifier had extremely good solvent 
properties for DHPS. The solubility of DHPS in the emulsifier 
was elevated to about 60,000 times that in water.
selection of surfactant and co-surfactant
To select an ideal surfactant, the solubility of DHPS, the 
hydrophile–lipophile balance (HLB), and toxicity to the human 
body must be considered seriously. Based on solubility studies, 
both EL-40 and Tween-80 showed considerable solubility of 
DHPS, and appropriate HLB value (range 8 to 16). Because 
non-ionic surfactants facilitate the adjustment of the interfacial 
tension, they are appropriate candidates for favorable emulsi-
fiers, as they exhibit low toxicity and play important roles in 
the drug delivery system. But as the results in Table 1 show, 
no phase change appears (no nanoemulsion was formed) when 
Tween-80 was the surfactant, no matter which alcohol was 
used as co-surfactant, and no matter under which ratios. In con-
trast, the mixture of EL-40 with four types of co-surfactant in 
certain proportions facilitated the formation of nanoemulsions 
and, therefore, more choices were available for the selection 
of the co-surfactant formulation. In view of this investigation, 
the selection of EL-40 as the surfactant in the preparation of 
the DHPS nanoemulsion was appropriate.
Table 1 Impacts of surfactants and co-surfactants on the nanoemulsion formation
Surfactants Co-surfactants Smix/oil
9:1 8:2 7:3 6:4 5:5 4:6 3:7 2:8 1:9
eL-40 ethanol √ √ √ – – – – – –
n-butanol √ √ – – – – – – –
i-propanol √ √ – – – – – – –
1,2-propanediol √ √ √ – – – – – –
Tween-80 ethanol – – – – – – – – –
n-butanol – – – – – – – – –
i-propanol – – – – – – – – –
1,2-propanediol – – – – – – – – –
Notes: √ represents the formation of nanoemulsion; – represents the absence of formation of nanoemulsion.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 2 The ternary phase diagram under different conditions.
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A good co-surfactant can improve the dispersibility of 
droplets and drug absorption.39 EL-40 was combined with 
four different co-surfactants including i-propanol, 1,2-
propanediol, n-butanol and ethanol, in different mass ratios, 
respectively. The results are shown in Figure 2. All four 
co-surfactants can promote the formation of nanoemulsions 
when Km is taken as 9:1; the nanoemulsion region was the 
largest when 1,2-propanediol was used for the co-surfactant. 
No clear transitional phase inversion appears when Km is 
taken as 8:2 and n-butanol is taken as co-surfactant. At 
a Km of 7:3, only ethanol can arrange EL-40 in pairs to 
generate phase inversion. When i-propanol served as the 
co-surfactant, the area of nanoemulsion was relatively small 
and, in comparison, the areas of nanoemulsion in phase 
diagrams are larger when 1,2-propanediol or ethanol are 
used. Among these two co-surfactants, a larger amount of 
surfactants are required when 1,2-propanediol is used owing 
to its lower solubility of DHPS, which may be harmful to the 
skin. Therefore because ethanol is non-irritating, has gentle 
properties, no toxicity to the human body, and is the most 
common and readily available reagent, it was chosen to be 
the co-surfactant.
Optimization of the formulation
As Figure 3 shows, when Km = 6:1, a small amount of 
oil (5.2%) can be emulsified and the nanoemulsion region 
is faint. As the Km decreases, the nanoemulsion region 
increases, further increasing the proportion of co-surfactant 
(Km = 3:1); the nanoemulsion region increases to a large 
scale and a considerable amount of oil (15.6%) can be 
  emulsified. When Km decreases to 1.5:1, the co-surfactant 
occupies a bigger ratio and the nanoemulsion cannot be 
formed. Taking a comprehensive view of the   nanoemulsion 
Figure 5 The TeM image of DhPs nanoemulsion particles.
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Figure 6 The mean size of DhPs nanoemulsion droplets.
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Figure 4 The phase behavior of nanoemulsions with different smixs to oil.
Table 2 Physicochemical parameters of DhPs nanoemulsion (n = 3)
Parameter Results
ph  5.69 ± 0.08
refractive index 1.3875 ± 0.002
Viscosity/cP 3.25 ± 0.02
structure type O/W
region, and the lower amount of Smix (surfactant/
co-  surfactant) used in this system, we finally selected 
the Km ratio as 3:1, and the ratio of Smix to oil as 3:7. 
  Nanoemulsions prepared with this formulation were further 
studied for stability and potential clinical   application. Under 
this optimized ratio, the prepared DHPS nanoemulsions 
with different mass ratios of Smix to oil were photographed 
and are shown in Figure 4.
characterization analyses
Physicochemical properties of DhPs nanoemulsions
The pH, viscosity, refractive index, and structure type of 
DHPS nanoemulsions are shown in Table 2.
Morphology and size distribution of DhPs 
nanoemulsion
TEM can directly produce images of targets with high 
resolution. The morphology and structure of the optimal International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 7 FT-raman spectra.
Table 3 The stability of drug nanoemulsion (n = 3)
Condition pH Average 
diameter/nm
Percentage/%
0 d 5.69 ± 0.01 62.89 ± 0.09 99.78 ± 0.01
60°c,5 d 5.67 ± 0.01 63.19 ± 0.10 99.20 ± 0.03
60°c,10 d 5.64 ± 0.01 62.01 ± 0.08 98.37 ± 0.05
4500 ± 500 lx, 5 d 5.66 ± 0.01 63.12 ± 0.11 98.95 ± 0.02
4500 ± 500 lx, 10 d 5.63 ± 0.02 63.32 ± 0.12 98.45 ± 0.03
nanoemulsion formulation were observed using TEM. As 
seen in Figure 5, the nanoemulsion droplet is round and 
has a smooth margin with a mean size of about 60.88 nm 
(  Figure 6). The droplet size has a direct influence on the 
behavior of the nanoemulsion, especially the bioavailability 
of the delivered drug. In general, the smaller the droplet size 
in the nanoemulsion, the more favorable the expected result 
for in vivo application.
raman spectrum of DhPs nanoemulsion
DHPS and the DHPS nanoemulsion were detected by 
FT-Raman spectroscopy at laser 350 mW scanning 
from 50 cm-1 to 4000 cm-1. Because the surfactants and 
co-  surfactants have no clear characteristic scattering 
  absorbance, DHPS and the DHPS nanoemulsion have 
almost the same FT-Raman spectra. In Figure 7, the scat-
tering characteristic peaks at 1453 cm-1 are attributed to 
the conjugating aromatic rings in stilbene and there is 
an alkene scattering peak at 1652 cm-1. The peaks from 
2920 cm-1 to 2930 cm-1 and the peak at 1301 cm-1 indicate 
the i-propyl group of DHPS.
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ratio of EL-40 to ethanol (Km) of 3:1 was chosen, and 
the Smix to oil was selected at 3:7. This optimized DHPS 
nanoemulsion has stable physical and chemical properties, 
and also good stability. The nanoemulsion has dramatically 
improved the DHPS transdermal effect, and the osmotic 
quantity of DHPS from the nanoemulsion formulations 
is 273.15 µg ⋅ cm-2, significantly better than for the DHPS 
suspension (8.02 µg ⋅ cm-2).
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stability of the DhPs nanoemulsion
After centrifuging, there was no sign of phase separation, 
creaming or cracking, and the nanoemulsion was still clear 
and transparent, with no turbidity and no crystal precipita-
tion. The data in Table 3 show that there are no apparent 
changes in pH, drop size, and concentration of nanoemulsion, 
which indicates good stability of the nanoemulsion loaded 
with DHPS.
In vitro transdermal release
In order to optimize drug delivery and achieve an ideal 
therapeutic effect, we have incorporated the drug into the 
heart of nanoemulsion droplets. Therefore, it was extremely 
important to observe the release of DHPS from the nano-
emulsions in comparison with that of the drug. Because 
nanoemulsions provide better dispersion and larger contact 
surface area for drug molecules, an elevated solubility and 
permeability could be expected.
As seen from Figure 8, it is clear that DHPS released 
from nanoemulsion increases exponentially, while DHPS 
released from the drug suspension is rather low and almost 
constant. In a 12-hour period, the maximum accumulative 
osmotic quantity, Qt, of DHPS from the DHPS suspension is 
8.02 µg ⋅ cm-2, while the Qt of DHPS from DHPS nanoemul-
sion is up to 273.15 µg ⋅ cm-2. During a defined time period, 
the transdermal release of DHPS from the suspension and the 
nanoemulsion follows the zero order kinetics equation, and the 
slope of the line indicates the penetration rate, J (Table 4). It is 
clear that the penetration rate, J, of DHPS is 0.53 µg ⋅ cm-2 ⋅ h-1 
from the DHPS suspension, and 24.51 µg ⋅ cm-2 ⋅ h-1 from the 
DHPS nanoemulsion. Therefore, the DHPS nanoemulsion has 
demonstrated significant transdermal advantages.
Conclusion
We have reported a novel procedure to prepare DHPS nano-
emulsion and identified the optimal prescription through a 
number of experiments. With EL-40 as the surfactant, ethanol 
as the co-surfactant, and IPM as the oil phase, the DHPS 
nanoemulsion can be obtained with transparent appear-
ance, low viscosity, and a spherically uniform distribution 
of droplets as verified by TEM, Raman spectroscopy, and 
laser scattering analyzer. For an optimal formulation, a mass 
Table  4  The  accumulative  osmotic  quantity  (Qt)  and  the 
penetration rate (J)
Sample Regression curve R
Drug DhPs Qt = 0.53t + 1.73 0.9975
DhPs nanoemulsion Qt = 24.51t - 3.51 0.9914International Journal of Nanomedicine
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